Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) EBIT: 2012-2025

Historic EBIT for Agios Pharmaceuticals (AGIO) over the last 14 years, with Sep 2025 value amounting to -$116.9 million.

  • Agios Pharmaceuticals' EBIT fell 13.67% to -$116.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$475.6 million, marking a year-over-year decrease of 16.86%. This contributed to the annual value of -$425.7 million for FY2024, which is 8.75% down from last year.
  • Agios Pharmaceuticals' EBIT amounted to -$116.9 million in Q3 2025, which was up 8.02% from -$127.1 million recorded in Q2 2025.
  • Agios Pharmaceuticals' EBIT's 5-year high stood at -$90.6 million during Q1 2023, with a 5-year trough of -$127.1 million in Q2 2025.
  • For the 3-year period, Agios Pharmaceuticals' EBIT averaged around -$106.2 million, with its median value being -$105.8 million (2024).
  • As far as peak fluctuations go, Agios Pharmaceuticals' EBIT plummeted by 111.19% in 2021, and later climbed by 10.41% in 2023.
  • Quarterly analysis of 5 years shows Agios Pharmaceuticals' EBIT stood at -$104.8 million in 2021, then rose by 5.39% to -$99.2 million in 2022, then fell by 7.16% to -$106.3 million in 2023, then declined by 17.65% to -$125.0 million in 2024, then dropped by 13.67% to -$116.9 million in 2025.
  • Its last three reported values are -$116.9 million in Q3 2025, -$127.1 million for Q2 2025, and -$106.6 million during Q1 2025.